First Patient Dosed in IntelGenx’s Resumed BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
IntelGenx Corp. recently announced patient dosing has resumed in the ongoing Phase 2a (BUENA) clinical trial in patients with mild to moderate Alzheimer’s Disease (AD) under a previously amended protocol using higher doses of Montelukast VersaFilm.
“Resumption of patient dosing after a COVID-related interruption of the study of over one year is a significant milestone for this novel drug repurposing program, and we look forward to the BUENA trial producing valuable data that will provide more complete insight into the safety, feasibility, tolerability and efficacy of Montelukast VersaFilm in patients with mild to moderate AD,” said Dr. Horst Zerbe, IntelGenx’s CEO.
“A significant unmet medical need remains for safe and effective treatments for mild to moderate AD,” said Dr. Ludwig Aigner, a member of IntelGenx’s Scientific Advisory Board. “We believe that Montelukast VersaFilm has the potential to be disease-modifying, and we are excited to have resumed patient dosing in this proof of concept trial.”
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx’s superior film technologies, including VersaFilm, DisinteQ, VetaFilm, and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.
Total Page Views: 750
